Metabolic & Cardiometabolic
GLP-1 receptor agonist decreases insulin resistance
Strong support Metabolic & Cardiometabolic
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 1.00
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 0 contradict 0 tested null 0 mixed · 3 sources, 3 independent groups · 1 superseded — pooled inside a review, counted once
What the evidence shows
GLP-1 receptor agonists improve insulin resistance in PCOS (lower fasting insulin, HOMA-IR, fasting glucose).
The evidence (5)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Heise T et al 2026 · Diabetes Obes Metab | RCT | mixed # adjudicated calibration #17 (2026-08-19): abstract asserts significance ONLY for macupatide (GIP arm); dulaglutide (the claim-relevant GLP-1RA) M value +0.2 (10.4%) with no significance claimed — equivocal for this claim, not supporting | low | Phase 1b, randomised, double-blind, 12-week trial in people with TYPE 2 DIABETES on metformin (not PCOS), comparing the GIP receptor agonist macupatide, dulaglutide, and the combination, with hyperinsulinemic-euglycaemic clamps at baseline and 12 weeks. 'The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).' Significance is asserted only for the GIP arm - 'Macupatide alone significantly increased the M value and, to a lesser yet significant extent, ISR' - and the conclusion frames GLP-1 as the secretion arm: 'chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and ... combining GIP and GLP-1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP-1 therapy alone.' Whether dulaglutide's +10.4% M value was significant cannot be told from the abstract. OFF-SCOPE for this PCOS-scoped claim; quality low on Phase 1b size (n not stated), no placebo arm, and Eli Lilly sponsorship of a trial of two Lilly assets. |
| exenatide-2022 2022 | RCT | supports | moderate | Long-term follow-up of an RCT, n=160 overweight/obese infertile Chinese PCOS: exenatide vs metformin 12 wk, then metformin for all. Spontaneous pregnancy at wk 24: 29.2% (exenatide) vs 14.7% (metformin), p=0.03; total pregnancy at wk 64 ns (79.2% vs 76%). Regression: spontaneous pregnancy positively associated with weight reduction and HOMA-IR improvement IN EITHER GROUP — no between-arm IR comparison reported in this paper. ↩ SUPERSEDED — pooled in the review above, counted once |
| beinaglutide-2023 2023 | RCT | supports | moderate | Randomized OPEN-LABEL 12-week pilot, n=60 obese PCOS (Rotterdam), single centre: beinaglutide+metformin vs metformin alone. COMB superior for weight/WC (p<=0.003) and reduced fasting insulin, total testosterone and HOMA-IR vs MET. Open-label pilot, short duration, insulin-resistance result is a secondary endpoint. |
| Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, Tan B 2025 · Scientific Reports | meta-analysis | supports | moderate | Pooled RCTs in PCOS (13 trials; 397 GLP-1RA vs 330 metformin / 68 placebo): HOMA-IR reduced (MD -0.58; 95% CI -0.98 to -0.19; P = 0.004; I2 = 91%) and fasting insulin reduced (MD -1.40; 95% CI -2.65 to -0.15; P = 0.03), both driven by the metformin comparison; 2-h post-OGTT insulin -27.88 (95% CI -38.58 to -17.17). Fasting glucose was NOT reduced (MD -0.12; 95% CI -0.28 to 0.04; P = 0.14) - the previous extract's 'reduced fasting glucose' was wrong. Exenatide-dominant, 12-32 weeks, unregistered. |
| Buragohain S et al 2026 · Cureus 2026;18(4):e106751 | meta-analysis | supports | moderate | Systematic review and random-effects meta-analysis of 18 RCTs in overweight/obese women with PCOS (PROSPERO CRD42024576690; PRISMA 2020; RoB2; GRADE). GLP-1RAs reduced HOMA-IR vs control: SMD -0.38 (95% CI -0.61 to -0.16, p=0.001), I2=55%. Subgroups agree in direction - vs placebo MD -0.78 (-1.23 to -0.34), vs standard treatment MD -0.79 (-1.22 to -0.35), exenatide strongest at MD -1.01 (-1.47 to -0.56). Certainty of evidence was GRADE-moderate for HOMA-IR. Caveats: controls mix metformin with placebo; trials small pilots, 12-32 weeks; 7 of 18 trials from one Ljubljana group; venue Cureus. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.